Announcement under Regulation 30 (LODR)-Allotment
Filed with BSE · · 4 pages · English
Re: Allotment of 1,82,400 Equity Shares to Non-Promoter Allottees pursuant to conversion of 60,800 Warrants into Equity Shares, consequent to the 1:2 Bonus Issue. This is to inform you that Board of Directors of the Company had pursuant to the approval of Shareholders in their Extra-Ordinary General Meeting held on October 22, 2025, had allotted convertible warrants on preferential basis to Allott
Fredun Pharmaceuticals Ltd. on 6ix
Earlier from Fredun Pharmaceuticals
- Board Meeting Outcome for Allotment Of 1,82,400 Equity Shares To Non-Promoter Allottees Pursuant To Conversion Of 60,800 Warrants Into Equity Shares, Consequent To The 1: 2 Bonus Issue.
- Fredun Pharmaceuticals Ltd. Press Release Sep 22 2026
- Fredun Pharmaceuticals Ltd. Press Release Sep 15 2026
- Fredun Pharmaceuticals Ltd. Press Release Sep 08 2026
- Fredun Pharmaceuticals Ltd. Press Release Sep 04 2026
Later from Fredun Pharmaceuticals
- Revised Outcome Of Board Meeting Dated 03Rd October, 2026.
- Announcement under Regulation 30 (LODR)-Press Release / Media Release
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Follow Fredun Pharmaceuticals into a list and get an email when it puts out news.
Follow Fredun Pharmaceuticals